Press Release: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow Jones11-18
Change in fair 
 value of 
 derivative asset             -            -          (81)           - 
Other income 
 (expense), net              (3)         922           12          964 
                      ---------    ---------    ---------    --------- 
Loss before 
 provision for 
 income taxes            (5,732)      (4,912)     (15,260)     (16,934) 
Provision for 
income taxes                  -            -            -            - 
                      ---------    ---------    ---------    --------- 
Net loss 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders        $   (5,732)  $   (4,912)  $  (15,260)  $  (16,934) 
                      =========    =========    =========    ========= 
Comprehensive loss   $   (5,732)  $   (4,912)  $  (15,260)  $  (16,934) 
                      =========    =========    =========    ========= 
Net loss per share 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders, 
 basic and diluted   $    (2.83)  $   (15.25)  $    (8.85)  $   (59.95) 
                      =========    =========    =========    ========= 
Weighted-average 
 shares used in 
 computing net loss 
 per share 
 attributable to 
 Vaccinex, Inc. 
 common 
 stockholders, 
 basic and diluted    2,026,920      322,153    1,724,088      282,467 
                      =========    =========    =========    =========

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/551b0bc4-4495-4a65-aa21-a96daddf079e

(END) Dow Jones Newswires

November 18, 2024 08:30 ET (13:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment